1. Home
  2. Clinical Topics
  3. FDA approves Topamax for migraine prevention in adolescents
Clinical TopicsDrugs and DevicesNewsPediatricsWeb Exclusives

FDA approves Topamax for migraine prevention in adolescents

Share

On March 28, the U.S. Food and Drug Administration approved Topamax (topiramate) for prevention of migraine headaches in adolescents ages 12 to 17. This is the first FDA approval of a drug for migraine prevention in this age group. Read more.

Leave a Reply

Your email address will not be published. Required fields are marked *

Fill out this field
Fill out this field
Please enter a valid email address.

cheryl meeGet your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.

NurseLine Newsletter

  • Hidden

*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.

Recent Posts